🇺🇸 CHRONO-INDOCID in United States

52 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 52

Most-reported reactions

1. Pulmonary Fibrosis — 8 reports (15.38%)
2. Pancytopenia — 7 reports (13.46%)
3. Pulmonary Sarcoidosis — 7 reports (13.46%)
4. Dizziness — 5 reports (9.62%)
5. Weight Decreased — 5 reports (9.62%)
6. Abdominal Pain — 4 reports (7.69%)
7. Abdominal Pain Lower — 4 reports (7.69%)
8. Appendicitis — 4 reports (7.69%)
9. Asthenia — 4 reports (7.69%)
10. Crohn^S Disease — 4 reports (7.69%)

Source database →

Frequently asked questions

Is CHRONO-INDOCID approved in United States?

CHRONO-INDOCID does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for CHRONO-INDOCID in United States?

Genfit is the originator. The local marketing authorisation holder may differ — check the official source linked above.